{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:22:06Z","timestamp":1774459326523,"version":"3.50.1"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T00:00:00Z","timestamp":1384473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0081919","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T23:05:57Z","timestamp":1384556757000},"page":"e81919","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Novel Immunocytokine IL12-SS1 (Fv) Inhibits Mesothelioma Tumor Growth in Nude Mice"],"prefix":"10.1371","volume":"8","author":[{"given":"Heungnam","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,11,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"K Chang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"K Chang","year":"1992","journal-title":"Int J Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","author":"NG Ord\u00f3\u00f1ez","year":"2003","journal-title":"Mod Pathol"},{"key":"ref4","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"P Argani","year":"2001","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of mesothelin in epithelial ovarian cancer","volume":"13","author":"R Hassan","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1158\/1078-0432.CCR-06-2161","article-title":"Mesothelin expression in human lung cancer","volume":"13","author":"M Ho","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.7150\/jca.1.141","article-title":"Mesothelin as a potential therapeutic target in human cholangiocarcinoma","volume":"1","author":"L Yu","year":"2010","journal-title":"J Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10549-012-2018-4","article-title":"Mesothelin, a novel immunotherapy target for triple negative breast cancer","volume":"133","author":"J Tchou","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"R Hassan","year":"2008","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"I Pastan","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1073\/pnas.95.2.669","article-title":"Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity","volume":"95","author":"PS Chowdhury","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/9872","article-title":"Improving antibody affinity by mimicking somatic hypermutation in vitro","volume":"17","author":"PS Chowdhury","year":"1999","journal-title":"Nat Biotechnol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"R Hassan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P","volume":"15","author":"RJ Kreitman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1093\/emboj\/19.14.3530","article-title":"Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin-12","volume":"19","author":"C Yoon","year":"2000","journal-title":"EMBO J"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.4049\/jimmunol.153.4.1697","article-title":"Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production","volume":"153","author":"CL Nastala","year":"1994","journal-title":"J Immunol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.coi.2009.03.010","article-title":"How are T(H)1 and T(H)2 effector cells made?","volume":"21","author":"D Amsen","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/019262339902700112","article-title":"The toxicology of interleukin-12: a review","volume":"27","author":"BD Car","year":"1999","journal-title":"Toxicol Pathol"},{"key":"ref19","first-page":"3202","article-title":"Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha","volume":"63","author":"C Halin","year":"2003","journal-title":"Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/ijc.22101","article-title":"An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties","volume":"119","author":"V Gafner","year":"2006","journal-title":"Int J Cancer"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1158\/1078-0432.CCR-12-0282","article-title":"The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel","volume":"18","author":"N Pasche","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1158\/1078-0432.CCR-04-2304","article-title":"Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients","volume":"11","author":"M Ho","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.7150\/jca.2.123","article-title":"In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice","volume":"2","author":"M Feng","year":"2011","journal-title":"J Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2174\/1381612003400597","article-title":"Cytokine therapy for cancer","volume":"6","author":"M Tagawa","year":"2000","journal-title":"Curr Pharm Des"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"G Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.1996.14.10.2653","article-title":"Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial","volume":"14","author":"AM Eggermont","year":"1996","journal-title":"J Clin Oncol"},{"key":"ref27","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"JP Leonard","year":"1997","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/blood.V91.1.196","article-title":"Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells","volume":"91","author":"AB Geldhof","year":"1998","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1084\/jem.177.4.1199","article-title":"Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells","volume":"177","author":"R Manetti","year":"1993","journal-title":"J Exp Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0008-8749(92)90011-D","article-title":"Regulation of human cytolytic lymphocyte responses by interleukin-12","volume":"143","author":"MK Gately","year":"1992","journal-title":"Cell Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1359-6101(01)00032-6","article-title":"Interleukin-12 in anti-tumor immunity and immunotherapy","volume":"13","author":"MP Colombo","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1165\/ajrcmb.19.5.3257m","article-title":"Interleukin-12 induces an effective antitumor response in malignant mesothelioma","volume":"19","author":"I Caminschi","year":"1998","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and antimetastatic activity of interleukin 12 against murine tumors","volume":"178","author":"MJ Brunda","year":"1993","journal-title":"J Exp Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00062752-199704010-00010","article-title":"Function and clinical use of interleukin-12","volume":"4","author":"G Trinchieri","year":"1997","journal-title":"Curr Opin Hematol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.4049\/jimmunol.158.7.3359","article-title":"IL-12 induces T helper 1-directed antitumor response","volume":"158","author":"K Tsung","year":"1997","journal-title":"J Immunol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/meth.1999.0836","article-title":"Interleukin-12 as an adjuvant for cancer immunotherapy","volume":"19","author":"M Rodolfo","year":"1999","journal-title":"Methods"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1158\/1535-7163.MCT-06-0342","article-title":"A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas","volume":"6","author":"F Siddiqui","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4049\/jimmunol.154.1.116","article-title":"Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity","volume":"154","author":"P Ling","year":"1995","journal-title":"J Immunol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ijc.11279","article-title":"Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells","volume":"106","author":"C Heuser","year":"2003","journal-title":"Int J Cancer"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1535-7163.MCT-05-0488","article-title":"Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2\/neu expressing tumors","volume":"5","author":"G Helguera","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00262-006-0203-1","article-title":"huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models","volume":"56","author":"KM Lo","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/protein\/gzq038","article-title":"Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12","volume":"23","author":"R Sommavilla","year":"2010","journal-title":"Protein Eng Des Sel"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/1535-7163.MCT-08-0945","article-title":"A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity","volume":"8","author":"Y Feng","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/ijc.25557","article-title":"A novel high-affinity human monoclonal antibody to mesothelin","volume":"128","author":"M Ho","year":"2011","journal-title":"Int J Cancer"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1158\/1535-7163.MCT-12-0731","article-title":"A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface","volume":"12","author":"Z Tang","year":"2013","journal-title":"Mol Cancer Ther"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0081919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T15:29:04Z","timestamp":1688657344000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0081919"}},"subtitle":[],"editor":[{"given":"Michael","family":"Platten","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,11,15]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,11,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0081919","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,15]]}}}